Search

Your search keyword '"Andrew Martin"' showing total 10 results
Start Over Author "Andrew Martin" Publisher biomed central
10 results on '"Andrew Martin"'

2. Knowledge, attitude and practice of healthcare workers on isoniazid preventive treatment in Tanzania; a health facility-based cross-sectional study

Author

Mshiu, Johnson Jeremia, Alexander, Felix Christopher, Rushaigo, Anelisa Martin, Nyigo, Vitus Alberto, Majaha, Melkisedeck Lolakeha, Maokola, Werner Meinrad, Ngowi, Bernard James, Wiketye, Victor Enock, Kimbute, Omari Abdallah, Mgina, Erick Josephat, Makasi, Charles Elias, Range, Nyagosya Segere, and Kilale, Andrew Martin

Published
2024
Full Text
View/download PDF

3. Phylogenetic lineages of tuberculosis isolates and their association with patient demographics in Tanzania

Author

Mutayoba, Beatrice Kemilembe, Michael Hoelscher, Heinrich, Norbert, Joloba, Moses L., Lyamuya, Eligius, Kilale, Andrew Martin, Range, Nyagosya Segere, Ngowi, Bernard James, Ntinginya, Nyanda Elias, Mfaume, Saidi Mwinjuma, Wilfred, Amani, Doulla, Basra, Lyimo, Johnson, Kisonga, Riziki, Kingalu, Amri, Kabahita, Jupiter Marina, Guido, Ocung, Kabugo, Joel, Adam, Isa, Luutu, Moses, Namaganda, Maria Magdalene, Namutebi, Joanitah, Kasule, George William, Nakato, Hasfah, Byabajungu, Henry, Lutaaya, Pius, Musisi, Kenneth, Oola, Denis, Mboowa, Gerald, and Pletschette, Michel

Published
2022
Full Text
View/download PDF

4. Economic burden of tuberculosis in Tanzania: a national survey of costs faced by tuberculosis-affected households

Author

Kilale, Andrew Martin, Pantoja, Andrea, Jani, Bhavin, Range, Nyagosya, Ngowi, Bernard James, Makasi, Charles, Majaha, Melkisedeck, Manga, Chacha Dionis, Haule, Sylvia, Wilfred, Amani, Hilary, Pudensiana, Mahamba, Vishnu, Nkiligi, Emmanuel, Muhandiki, Wilbard, Matechi, Emmanuel, Mutayoba, Beatrice, Nishkiori, Nobuyuki, and Ershova, Julia

Published
2022
Full Text
View/download PDF

6. Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from Romania

Author

Oliviu Pascu, Ioan Sporea, Manuela Curescu, Anca Victorița Trifan, Florin Alexandru Caruntu, Mihai Mircea Diculescu, Sorin Rugină, Mihai Voiculescu, I. Lonjon-Domanec, Liliana Gheorghe, Andrew Martin Hill, and Adrian Streinu-Cercel

Subjects
Pediatrics, medicine.medical_specialty, Pathology, business.industry, Hepatitis C, medicine.disease, Telaprevir, Infectious Diseases, Genotype, Poster Presentation, Medicine, In patient, business, medicine.drug
Abstract

Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from Romania Adrian Streinu-Cercel, Anca Victorița Trifan, Florin Alexandru Caruntu, Ioan Sporea, Liliana Simona Gheorghe, Manuela Curescu, Mihai Mircea Diculescu, Mihai Voiculescu, Oliviu Pascu, Isabelle Lonjon-Domanec, Andrew Martin Hill, Sorin Rugina

Published
2013

7. Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania

Author

Florin Alexandru Caruntu, Sorin Rugină, Mihai Mircea Diculescu, I. Lonjon-Domanec, Mihai Voiculescu, Andrew Martin Hill, Ioan Sporea, Oliviu Pascu, Manuela Curescu, Anca Victorița Trifan, Liliana Gheorghe, and Adrian Streinu-Cercel

Subjects
medicine.medical_specialty, Pathology, Cirrhosis, Population, Peginterferon-alfa, Gastroenterology, Telaprevir, chemistry.chemical_compound, Internal medicine, medicine, education, education.field_of_study, Intention-to-treat analysis, medicine.diagnostic_test, business.industry, Ribavirin, virus diseases, Hepatitis C, medicine.disease, digestive system diseases, Infectious Diseases, chemistry, Liver biopsy, Poster Presentation, business, medicine.drug
Abstract

Methods Patients were treated with telaprevir in combination with peginterferon alfa and ribavirin (PR) for 12 weeks, followed by PR for 12 or 36 weeks. Severe fibrosis/cirrhosis was defined by liver biopsy (Metavir F3-4 or Ishak 3-6) or noninvasive tests. Platelet count >90,000/cmm was required at entry. HCV RNA was evaluated at baseline and Weeks 4 and 12 of treatment. Virological response was defined as serum HCV RNA not detected, for the Intent to Treat (ITT) population.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results